Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROBERT A KOPPEL

Allopathic & Osteopathic Physicians Dermatology

NPI
1326066952
CMS profile
571637
Location
METAIRIE, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$26,947.62

138 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 138 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROBERT A KOPPEL

NPI 1326066952 · CMS profile ID 571637

Allopathic & Osteopathic Physicians / Dermatology

METAIRIE, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 138 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1326066952?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROBERT A KOPPEL, NPI 1326066952, CMS profile ID 571637. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 138 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1326066952?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ROBERT A KOPPEL, NPI 1326066952, CMS profile ID 571637. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 138 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1326066952?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ROBERT A KOPPEL, NPI 1326066952, CMS profile ID 571637, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 138 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1326066952?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

138 matching records · $26,947.62 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 138 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 138.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $22.1410/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843523655 CMS
AbbVie Inc. $15.7310/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795145463 CMS
GENZYME CORPORATION $11.0910/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843523659 CMS
ORGANOGENESIS INC. $21.8910/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835468103 CMS
AbbVie Inc. $4.4910/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795145455 CMS
AbbVie Inc. $3.1310/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795145459 CMS
Amgen Inc. $20.9309/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826419479 CMS
GENZYME CORPORATION $8.0809/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843523649 CMS
Regeneron Healthcare Solutions, Inc. $14.9609/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809595627 CMS
AbbVie Inc. $22.3709/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795145447 CMS
AbbVie Inc. $4.3609/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795145451 CMS
GENZYME CORPORATION $21.4709/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843523647 CMS
VYNE Pharmaceuticals Inc. $36.6108/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830818829 CMS
GENZYME CORPORATION $10.0308/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843523631 CMS
Novartis Pharmaceuticals Corporation $12.3108/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812756755 CMS
AbbVie Inc. $2.1708/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795145443 CMS
MAYNE PHARMA INC. $20.2008/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849501089 CMS
Regeneron Healthcare Solutions, Inc. $21.5708/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809595625 CMS
MAYNE PHARMA INC. $19.3607/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849459405 CMS
Amgen Inc. $18.5107/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826419475 CMS
GENZYME CORPORATION $15.0407/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843523623 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $5.6307/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849564829 CMS
UCB, Inc. $5.1207/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807374511 CMS
Janssen Biotech, Inc. $14.7307/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788114001 CMS
PFIZER INC. $20.3107/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832537503 CMS
GENZYME CORPORATION $20.9807/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843523499 CMS
SANOFI-AVENTIS U.S. LLC $14.5007/19/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843523531 CMS
GENZYME CORPORATION $12.0907/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843523503 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $15.7707/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851922673 CMS
Amgen Inc. $22.4006/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826419471 CMS
AbbVie Inc. $12.2106/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795145439 CMS
GENZYME CORPORATION $22.9406/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843523483 CMS
Medimetriks Pharmaceuticals, Inc. $25.6506/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803510603 CMS
LEO Pharma Inc. $14.5906/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842216993 CMS
Genentech USA, Inc. $21.4106/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835968185 CMS
Janssen Biotech, Inc. $21.9806/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788114005 CMS
Regeneron Healthcare Solutions, Inc. $20.7606/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809595623 CMS
PFIZER INC. $13.1706/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832521227 CMS
Novartis Pharmaceuticals Corporation $22.8605/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812756753 CMS
AbbVie Inc. $22.6705/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795145431 CMS
AbbVie Inc. $6.0305/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795145435 CMS
GENZYME CORPORATION $13.3205/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843523471 CMS
Janssen Biotech, Inc. $15.1505/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788114013 CMS
UCB, Inc. $6.0205/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807344245 CMS
Lilly USA, LLC $26.2405/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818677121 CMS
LEO Pharma Inc. $24.1505/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842216983 CMS
Amgen Inc. $22.8205/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826419467 CMS
Janssen Biotech, Inc. $13.0805/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788114021 CMS
PFIZER INC. $12.0605/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832491195 CMS
PFIZER INC. $3.7505/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832508411 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $16,918.51 102
PY2020 $7,938.71 100
PY2021 $26,947.62 138
PY2022 $56,767.13 195
PY2023 $54,733.36 225
PY2024 $25,872.73 177
PY2025 $23,186.90 161

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $68,300.46 120
PY2024 Principal investigator $177,213.90 334
PY2023 Principal investigator $123,038.02 57
PY2022 Principal investigator $58,812.27 15
PY2021 Principal investigator $12,238.08 21
PY2020 Principal investigator $67,712.68 15
PY2019 Principal investigator $158,247.72 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

120 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $2,998.80 12/08/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519278
Principal investigator 1 Incyte Corporation $49.77 12/01/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519270
Principal investigator 1 Incyte Corporation $2.37 12/01/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519293
Principal investigator 1 Incyte Corporation $9.48 12/01/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519297
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519301
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519305
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519309
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519314
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519318
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519322
Principal investigator 1 Incyte Corporation $1,380.60 11/24/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519274
Principal investigator 1 Incyte Corporation $1,782.90 11/12/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519289
Principal investigator 1 Incyte Corporation $135.40 11/03/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519286
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $15,771.69 10/27/2025 Non-covered Recipient Entity
Clinical Trials Management
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) No dispute reported 06/30/2026 1235997984
Principal investigator 1 Incyte Corporation $2,087.10 10/20/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519266
Principal investigator 1 Incyte Corporation $2,352.60 10/08/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519282
Principal investigator 1 Incyte Corporation $1,264.50 10/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519326
Principal investigator 1 Incyte Corporation $1,755.90 08/01/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519256
Principal investigator 1 Incyte Corporation $1,264.50 07/18/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519252
Principal investigator 1 Incyte Corporation $1,143.00 07/18/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519259
Principal investigator 1 Incyte Corporation $1,755.90 07/09/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519263
Principal investigator 1 Incyte Corporation $1,500.00 06/11/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519142
Principal investigator 1 Incyte Corporation $1,755.90 06/11/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519147
Principal investigator 1 Incyte Corporation $1,500.00 06/11/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519225
Principal investigator 1 Incyte Corporation $9.27 06/03/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519188
Principal investigator 1 Incyte Corporation $16.18 06/03/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519200
Principal investigator 1 Incyte Corporation $34.35 06/03/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519205
Principal investigator 1 Incyte Corporation $1,534.00 05/21/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519117
Principal investigator 1 Incyte Corporation $1,761.80 05/21/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519123
Principal investigator 1 Incyte Corporation $1,782.90 05/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519138
Principal investigator 1 Incyte Corporation $16.18 05/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519192
Principal investigator 1 Incyte Corporation $2.43 05/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519196
Principal investigator 1 Incyte Corporation $11.45 05/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519229
Principal investigator 1 Incyte Corporation $2.43 05/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519233
Principal investigator 1 Incyte Corporation $2,157.50 04/09/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519100
Principal investigator 1 Incyte Corporation $1,951.00 04/09/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519120
Principal investigator 1 Incyte Corporation $49.36 04/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519105
Principal investigator 1 Incyte Corporation $1,032.60 04/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519110
Principal investigator 1 Incyte Corporation $2,319.00 04/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519114
Principal investigator 1 Incyte Corporation $10.76 04/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519127
Principal investigator 1 Incyte Corporation $95.40 04/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519131
Principal investigator 1 Incyte Corporation $16.44 04/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519136
Principal investigator 1 Incyte Corporation $34.35 04/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519151
Principal investigator 1 Incyte Corporation $24.68 04/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519154
Principal investigator 1 Incyte Corporation $11.45 04/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519158
Principal investigator 1 Incyte Corporation $5.30 04/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519163
Principal investigator 1 Incyte Corporation $8.22 04/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519167
Principal investigator 1 Incyte Corporation $16.44 04/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519171
Principal investigator 1 Incyte Corporation $16.44 04/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519174
Principal investigator 1 Incyte Corporation $16.44 04/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519179
Principal investigator 1 Incyte Corporation $4.86 04/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519184
Principal investigator 1 Incyte Corporation $5.38 04/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519208
Principal investigator 1 Incyte Corporation $26.90 04/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519212
Principal investigator 1 Incyte Corporation $0.31 04/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519217
Principal investigator 1 Incyte Corporation $14.42 04/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519221
Principal investigator 1 Incyte Corporation $8.22 04/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519237
Principal investigator 1 Incyte Corporation $8.22 04/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519239
Principal investigator 1 Incyte Corporation $8.22 04/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519244
Principal investigator 1 Incyte Corporation $121.90 04/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519247
Principal investigator 1 Incyte Corporation $1,881.00 03/12/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518880
Principal investigator 1 Incyte Corporation $62.27 03/03/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518978
Principal investigator 1 Incyte Corporation $45.80 03/03/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518994
Principal investigator 1 Incyte Corporation $1,264.50 03/03/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519049
Principal investigator 1 Incyte Corporation $1,755.90 02/10/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518864
Principal investigator 1 Incyte Corporation $1,361.70 01/27/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518876
Principal investigator 1 Incyte Corporation $1,472.00 01/15/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518857
Principal investigator 1 Incyte Corporation $1,759.00 01/15/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518860
Principal investigator 1 Incyte Corporation $1,405.00 01/15/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518869
Principal investigator 1 Incyte Corporation $1,405.00 01/15/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519044
Principal investigator 1 Incyte Corporation $1,951.00 01/15/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519061
Principal investigator 1 Incyte Corporation $137.80 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518872
Principal investigator 1 Incyte Corporation $180.20 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518883
Principal investigator 1 Incyte Corporation $190.80 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518887
Principal investigator 1 Incyte Corporation $42.40 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518890
Principal investigator 1 Incyte Corporation $137.80 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518894
Principal investigator 1 Incyte Corporation $58.30 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518898
Principal investigator 1 Incyte Corporation $63.60 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518901
Principal investigator 1 Incyte Corporation $106.00 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518906
Principal investigator 1 Incyte Corporation $90.10 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518909
Principal investigator 1 Incyte Corporation $53.00 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518913
Principal investigator 1 Incyte Corporation $21.20 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518917
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518922
Principal investigator 1 Incyte Corporation $31.80 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518927
Principal investigator 1 Incyte Corporation $31.80 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518930
Principal investigator 1 Incyte Corporation $43.04 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518934
Principal investigator 1 Incyte Corporation $43.04 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518939
Principal investigator 1 Incyte Corporation $21.52 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518942
Principal investigator 1 Incyte Corporation $9.72 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518946
Principal investigator 1 Incyte Corporation $16.44 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518949
Principal investigator 1 Incyte Corporation $16.44 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518952
Principal investigator 1 Incyte Corporation $15.90 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518956
Principal investigator 1 Incyte Corporation $15.90 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518960
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518965
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518971
Principal investigator 1 Incyte Corporation $5.38 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518974
Principal investigator 1 Incyte Corporation $16.44 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518982
Principal investigator 1 Incyte Corporation $4.24 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518986
Principal investigator 1 Incyte Corporation $8.24 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518990
Principal investigator 1 Incyte Corporation $95.40 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240518997
Principal investigator 1 Incyte Corporation $42.40 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519001
Principal investigator 1 Incyte Corporation $10.60 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519007
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519012
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519016
Principal investigator 1 Incyte Corporation $37.10 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519019
Principal investigator 1 Incyte Corporation $16.44 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519022
Principal investigator 1 Incyte Corporation $16.44 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519030
Principal investigator 1 Incyte Corporation $16.44 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519034
Principal investigator 1 Incyte Corporation $16.44 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519036
Principal investigator 1 Incyte Corporation $16.44 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519041
Principal investigator 1 Incyte Corporation $132.50 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519052
Principal investigator 1 Incyte Corporation $132.50 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519058
Principal investigator 1 Incyte Corporation $58.30 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519065
Principal investigator 1 Incyte Corporation $58.30 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519068
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519072
Principal investigator 1 Incyte Corporation $31.80 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519076
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519080
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519084
Principal investigator 1 Incyte Corporation $53.00 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519088
Principal investigator 1 Incyte Corporation $21.52 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519092
Principal investigator 1 Incyte Corporation $21.52 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240519097